Company Description
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain.
Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial.
It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2.
The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2020 |
| IPO Date | Jan 7, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Ivana Magovcevic-Liebisch |
Contact Details
Address: 100 Forge Road, Suite 700 Watertown, Massachusetts 02472 United States | |
| Phone | 857 254 4445 |
| Website | vigilneuro.com |
Stock Details
| Ticker Symbol | VIGL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001827087 |
| CUSIP Number | 92673K108 |
| ISIN Number | US92673K1088 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. | President, Chief Executive Officer and Director |
| Jennifer Ziolkowski CPA | Chief Financial Officer |
| Dr. David Gray Ph.D. | Chief Scientific Officer |
| Sharon Morani | Senior Director of Facilities and Operations |
| Leah Gibson | Vice President of Investor Relations and Corporate Communications |
| Christopher Verni J.D. | General Counsel and Corporate Secretary |
| April Effort M.B.A., M.S. | Vice President and Head of Corporate Development |
| Evan A. Thackaberry DABT, Ph.D. | Senior Vice President and Head of Early Development |
| Christian Mirescu Ph.D. | Senior Vice President and Head of Neuroimmunology |
| Weeteck Yeo Ph.D. | Senior Vice President of Strategic Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 9, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 19, 2024 | 144 | Filing |
| Sep 17, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Aug 13, 2024 | 8-K | Current Report |
| Aug 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jul 24, 2024 | 8-K | Current Report |
| Jul 18, 2024 | 8-K | Current Report |
| Jun 27, 2024 | 8-K | Current Report |
| Jun 6, 2024 | 8-K | Current Report |